ArticleEClinicalMedicine2025

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Tingyu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.